Fletcher Spaght, Inc.
VC Fund
Boston, United States
Fletcher Spaght, Inc. is a VC fund in Boston focused on Biotechnology and Health Care. Strategy consulting to innovate and accelerate organic and inorganic growth. We have a deep reputation for developing actionable insights that are typically delivered as a growth plan.
- Total investments:
- 32
- Last investment:
- Lead investor:
- 9%
Last updated:
For AI agents: llms.txt
Industries Fletcher Spaght, Inc. invests in
BiotechnologyHealth CareMedicalMedical DeviceLife Science
Stages Fletcher Spaght, Inc. invests in
Series CSeries BSeries DFunding RoundSeries A
Countries Fletcher Spaght, Inc. invests in
United States
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Bob Schmidt
|
|||
|
Janice DiSanto
|
|||
John Fletcher
|
|||
Linda Tufts
|
|||
Lisa Granick
|
|||
| See all 8 contacts → | |||
Investment Focus
Industry
- Biotechnology 13 (41%)
- Health Care 9 (28%)
- Medical 8 (25%)
- Medical Device 6 (19%)
- Life Science 4 (13%)
Stage
- Series C 9 (28%)
- Series B 7 (22%)
- Series D 5 (16%)
- Funding Round 4 (13%)
- Series A 2 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Bob Schmidt
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
|
Janice DiSanto
Director of Finance and Administration
|
Director of Finance and Administration | Total investments: 0 | Find email | |
|
John Fletcher
Co-Founder & Managing Partner
|
Co-Founder & Managing Partner | Total investments: 1 | Find email | |
|
Linda Tufts
General Partner and Co-Founder
|
General Partner and Co-Founder | Total investments: 1 | Find email | |
|
Lisa Granick
Senior Vice President
|
Senior Vice President | Total investments: 2 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
PhaseBio Pharmaceuticals
|
PhaseBio is a clinical-stage biopharmaceutical company committed to developing new and improved drugs, with an initial focus on endocrine and metabolic disorders and cardiovascular disease. The company uses its proprietary recombinant biopolymers called elastin-like polypeptides (ELPs) to improve the stability, bioavailability, activity, and easeof administration of proteins and peptides, with the goal of achieving greater potency, fewer side effects, and better patient compliance. Efficient production in E. coli ensures a low cost of goods.PhaseBio’s lead drug candidate, PB1023, is currently being evaluated in a phase 2b clinical trial for the treatment of hyperglycemia associated with type 2 diabetes, with potential for future use in the treatment of obesity. Our second drug candidate, Vasomera, is currently being evaluated in phase 1 clinical trial and has exciting potential for use in the treatment of pulmonary arterial hypertension (PAH) and heart failure. Its third program, Insumera, basal insulin based on native human insulin, will enter clinical trials in early 2013.PhaseBio is based in Malvern, Pennsylvania. | $34M / Series D / Sep 05, 2018 | |
Cheetah Medical
|
Cheetah’s proprietary CHEETAH NICOM system is CE marked and FDA cleared. It is the only non-invasive cardiac output monitor with substantial equivalence to the Swan Ganz thermodilution system for U.S. regulatory purposes. The CHEETAH NICOM is now used by leading medical centers around the globe providing clinicians with invaluable clinicalinformation in complicated scenarios. Cheetah Medical is committed to ongoing research and development and close cooperation with clinicians. | $11.8M / Series C / Sep 12, 2017 | |
HistoSonics
|
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels. | $8.3M / Series B / Mar 13, 2017 | |
|
PhaseBio Pharmaceuticals
|
PhaseBio is a clinical-stage biopharmaceutical company committed to developing new and improved drugs, with an initial focus on endocrine and metabolic disorders and cardiovascular disease. The company uses its proprietary recombinant biopolymers called elastin-like polypeptides (ELPs) to improve the stability, bioavailability, activity, and easeof administration of proteins and peptides, with the goal of achieving greater potency, fewer side effects, and better patient compliance. Efficient production in E. coli ensures a low cost of goods.PhaseBio’s lead drug candidate, PB1023, is currently being evaluated in a phase 2b clinical trial for the treatment of hyperglycemia associated with type 2 diabetes, with potential for future use in the treatment of obesity. Our second drug candidate, Vasomera, is currently being evaluated in phase 1 clinical trial and has exciting potential for use in the treatment of pulmonary arterial hypertension (PAH) and heart failure. Its third program, Insumera, basal insulin based on native human insulin, will enter clinical trials in early 2013.PhaseBio is based in Malvern, Pennsylvania. | $40M / Series C / Mar 12, 2015 | |
CardioFocus
|
CardioFocus is a biotechnology company that focuses on the advancement of ablation treatments for cardiac disorders. The company specializes in providing electrophysiologists with innovative and effective tools that bring new levels of precision and control to the treatment of atrial fibrillation that focuses on developing, manufacturing, andinvestigating disposable fiber optic catheters for the visualization of the cardiac anatomy and the treatment of cardiac arrhythmias.CardioFocus was founded in 1990 and is headquartered in Marlborough, Massachusetts. | Debt Financing / May 09, 2014 | |
|
Cheetah Medical
|
Cheetah’s proprietary CHEETAH NICOM system is CE marked and FDA cleared. It is the only non-invasive cardiac output monitor with substantial equivalence to the Swan Ganz thermodilution system for U.S. regulatory purposes. The CHEETAH NICOM is now used by leading medical centers around the globe providing clinicians with invaluable clinicalinformation in complicated scenarios. Cheetah Medical is committed to ongoing research and development and close cooperation with clinicians. | $28.8M / Series C / Feb 24, 2014 | |
Metabolon
|
Metabolon is a technology company, develops analytical methods and software for biomarker discovery using metabolomics. It offers a biochemical profiling platform that analyzes and identifies biochemicals in the research of pharmaceutical, biotech, agriculture, cosmetic, and consumer products. Metabolon provides a unique, real-time fingerprint ofbiological system to reveal novel discoveries and realize the promise of precision medicine.The company can deliver an instantaneous snapshot of the entire physiology of a living being at a discreet point in time, as well as identify changes in that system brought about the impact of the disease, medical intervention, diet, or the environment. This deep and comprehensive view of the metabolome provides biological insights that cannot be revealed through any other research methodology, enabling life sciences researchers and drug developers to discover answers to some of biology’s most difficult questions.Metabolon was founded in 2000 and headquartered in Durham, North Carolina. | $15M / Series E / Jan 06, 2014 | |
Swift Biosciences
|
Swift Biosciences, Inc. develops molecular biology reagents for research and diagnostic applications. Swift Biosciences, Inc. is based in Ann Arbor, Michigan. | $7M / Series B / Oct 17, 2013 | |
SurgiQuest
|
Surgiquest offers technology solutions for minimally invasive surgery. It offers AirSeal, a technology that creates an air curtain that maintains an insufflated and airtight environment and has application in laparoscopic and laparoscopic-assisted surgery. The company focuses on bariatric, colorectal, general, gynecological, and urologic surgery.Surgiquest was incorporated in 2006 and is based in Orange, Connecticut. | $7.5M / Series D / Dec 05, 2012 | |
Juventas Therapeutics
|
Juventas Therapeutics is a privately-held clinical-stage biotechnology company developing a pipeline of regenerative therapies to treat life–threatening diseases. Founded in 2007 with an exclusive license from the Cleveland Clinic, Juventas has transitioned its therapeutic platform from concept to initiation of mid-stage clinical trials.Investors include Triathlon Medical Venture Partners, Early Stage Partners, Fletcher Spaght Ventures, Reservoir Venture Partners, North Coast Angel Fund, X Gen Ltd., JumpStart Inc., and Blue Chip Venture Co. The company has received nondilutive grant support through the Ohio Third Frontier funded Cleveland Clinic Ohio BioValidation Fund, Global Cardiovascular Innovation Center and Center for Stem Cell & Regenerative Medicine. | $22.2M / Series B / Jul 16, 2012 | |
| See all 32 investments → | |||
Co-Investors
Hatteras Venture Partners
7 deals together
The Aurora Funds
5 deals together
Early Stage Partners
4 deals together
Johnson & Johnson Development Corporation
4 deals together
Oxford Bioscience Partners
3 deals together
SV Health Investors
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Medical Device Investors
11,047 investors
Life Science Investors
6,823 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
FAQ
What does Fletcher Spaght, Inc. invest in?
Fletcher Spaght, Inc. invests primarily in Biotechnology, Health Care and Medical startups, most often at Series C and Series B stage. Most of the 32 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Fletcher Spaght, Inc.?
Public channels for Fletcher Spaght, Inc. include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Fletcher Spaght, Inc.?
The team at Fletcher Spaght, Inc. includes Bob Schmidt (Venture Partner), Janice DiSanto (Director of Finance and Administration) and John Fletcher (Co-Founder & Managing Partner), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
